A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...
Investors interested in arranging a meeting with the Company's management during the conference can register on the BIO CEO & Investor Conference website here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback